Medicamen Biotech Ltd (MEDICAMEQ) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{ "main_header": { "sid": 770569, "name": "Medicamen Biotec", "stock_name": "Medicamen Biotec", "full_name": "Medicamen Biotech Ltd", "name_url": "stocks-analysis/medicamen-biotec", "exchange": 0, "exchangecode": "", "primexch": 1, "country_id": 34, "currency": "INR", "cmp": "225.70", "chg": -5.5, "chgp": "-2.38%", "dir": -1, "prev_price": "231.20", "mcapval": "308.00 Cr", "mcap": "Micro Cap", "scripcode": 531146, "symbol": "MEDICAMEQ", "ind_name": "Pharmaceuticals & Biotechnology", "ind_code": 4, "sector_id": 65, "indexname": "India SENSEX", "isin": "INE646B01010", "curr_date": "Jun 11, 03:30 PM", "curr_time": "08:05 AM", "last_traded_at": "Jun 11, 03:30 PM IST", "bse_nse_vol": "21.15 k", "exc_status": "Active", "traded_date": "Jun 11, 2026", "traded_date_str": "2026 06 11", "score": "", "scoreText": "", "Live": 0, "market_time": 0, "is_blur": 1, "is_blur_class": "blur-register-score-header", "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/medicamen-biotec-770569-0&utm_source=Spage_Header_Score", "mojoone": { "ismore": 0, "all_data": [] } }, "news": { "results": [ { "title": "Medicamen Biotech Ltd is Rated Sell", "link": "https://www.marketsmojo.com/news/stock-recommendation/medicamen-biotech-ltd-is-rated-sell-4046568", "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/MedicamenBiotec_mojoScore_4046568.png", "date": "2026-06-11 10:10:04", "description": "Medicamen Biotech Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 05 May 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 11 June 2026, providing investors with an up-to-date view of its performance and outlook." }, { "title": "Five Consecutive Losses Push Medicamen Biotech Ltd to a New 52-Week Low", "link": "https://www.marketsmojo.com/news/stocks-in-action/medicamen-biotech-ltd-stock-falls-to-52-week-low-of-rs21765-4038533", "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/MedicamenBiotec_priceRelatedfactors_4038533.png", "date": "2026-06-08 15:38:05", "description": "For the fifth consecutive session, Medicamen Biotech Ltd has closed lower, hitting a fresh 52-week low of Rs 217.65 on 8 Jun 2026. This marks a significant decline amid a broader market environment that itself is under pressure, but the stock’s underperformance is notably sharper." }, { "title": "Medicamen Biotech Gains 0.93%: 3 Key Factors Driving the Week", "link": "https://www.marketsmojo.com/news/stocks-in-action/medicamen-biotech-gains-093-3-key-factors-driving-the-week-4023150", "imagepath": "", "date": "2026-05-30 15:04:46", "description": " <div class=\"article-news-new\">\n <div class=\"article-container\">\n\n<div class=\"article-content\">\n <div class=\"highlight-box\">\n <h3>Key Events This Week</h3>\n <p><strong>25 May:</strong> Stock opens at Rs.270.85, rising 1.16% amid positive market sentiment</p>\n <p><strong>27 May:</strong> Strong Q4 FY26 results announced; valuation shifts to fair</p>\n <p><strong>29 May:</strong> Stock closes at Rs.270.25, down 4.52% on profit-taking despite quarterly turnaround</p>\n </div>\n\n <div class=\"stats-row\">\n <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=\"stat-value\">Rs.267.75</div></div>\n <div class=\"stat-item\"><div class=\"stat-label\">Week Close</div><div class=\"stat-value\">Rs.270.25</div><div class=\"stat-change positive\">+0...." }, { "title": "Medicamen Biotech Ltd Reports Strong Quarterly Turnaround Amid Long-Term Challenges", "link": "https://www.marketsmojo.com/news/stocks-in-action/medicamen-biotech-ltd-reports-strong-quarterly-turnaround-amid-long-term-challenges-4019150", "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/MedicamenBiotec_fintrenddot_4019150.png", "date": "2026-05-29 08:00:31", "description": "Medicamen Biotech Ltd has demonstrated a notable financial turnaround in the quarter ended March 2026, reversing a negative trend to post its highest quarterly revenue and profit metrics in recent history. Despite ongoing sector headwinds and a challenging broader market environment, the micro-cap pharmaceutical company’s latest results signal a potential inflection point in its operational performance." }, { "title": "Are Medicamen Biotech Ltd latest results good or bad?", "link": "https://www.marketsmojo.com/news/result-analysis/are-medicamen-biotech-ltd-latest-results-good-or-bad-4018953", "imagepath": "", "date": "2026-05-28 19:23:34", "description": "Medicamen Biotech Ltd's latest financial results for Q4 FY26 indicate a significant surge in revenue and net profit, with net sales reaching ₹60.65 crores, reflecting a year-on-year growth of 104.83%. The consolidated net profit also showed a notable increase of 59.50% compared to the same quarter last year, amounting to ₹3.86 crores. This growth trajectory is a marked improvement from the previous year's performance, where the company faced a decline in revenue.\n\nHowever, despite these positive figures, there are underlying concerns regarding the company's operational efficiency. The operating margin, excluding other income, has compressed to 8.97%, down from 9.34% in the previous quarter, continuing a trend of margin compression that has been observed over the past few years. This decline in margins raises questions about the sustainability of the profit growth, particularly as the company has shown a hea..." }, { "title": "Medicamen Biotech Ltd is Rated Sell", "link": "https://www.marketsmojo.com/news/stock-recommendation/medicamen-biotech-ltd-is-rated-sell-4018025", "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/MedicamenBiotec_mojoScore_4018025.png", "date": "2026-05-28 10:10:16", "description": "Medicamen Biotech Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 05 May 2026. However, the analysis and financial metrics presented here reflect the stock's current position as of 28 May 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and technical outlook." }, { "title": "Medicamen Biotech Q4 FY26: Strong Quarter Masks Deeper Structural Concerns", "link": "https://www.marketsmojo.com/news/result-analysis/medicamen-biotech-q4-fy26-strong-quarter-masks-deeper-structural-concerns-4017908", "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/MedicamenBiotec_quaterlyResult_4017908.png", "date": "2026-05-27 22:31:31", "description": "Medicamen Biotech Ltd., a research-led pharmaceutical company with presence across 40+ countries, reported consolidated net profit of ₹3.86 crores for Q4 FY26, marking a substantial 76.26% quarter-on-quarter surge and a 59.50% year-on-year increase. However, the micro-cap pharma player, with a market capitalisation of ₹370.00 crores, continues to grapple with structural profitability challenges, elevated valuation multiples, and persistent underperformance against sector benchmarks that have pushed the stock down 33.70% over the past year." }, { "title": "Medicamen Biotech Ltd Valuation Shifts to Fair Amidst Challenging Market Returns", "link": "https://www.marketsmojo.com/news/stocks-in-action/medicamen-biotech-ltd-valuation-shifts-to-fair-amidst-challenging-market-returns-4015593", "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/MedicamenBiotec_valuationdot_4015593.png", "date": "2026-05-27 08:01:06", "description": "Medicamen Biotech Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its valuation parameters, moving from an attractive to a fair rating. This change reflects evolving market perceptions amid challenging sector dynamics and a mixed financial performance, prompting investors to reassess the stock’s price attractiveness relative to its historical and peer benchmarks." }, { "title": "When is the next results date for Medicamen Biotech Ltd?", "link": "https://www.marketsmojo.com/news/result-analysis/when-is-the-next-results-date-for-medicamen-biotech-ltd-4003818", "imagepath": "", "date": "2026-05-21 23:18:14", "description": "The next results date for Medicamen Biotech Ltd is scheduled for 27 May 2026...." } ], "total": 6247, "sid": "770569", "stock_news_url": "https://www.marketsmojo.com/news/medicamen-biotech-770569" }, "announcements": [ { "caption": "Corporate Action-Board to consider Dividend", "datetime": "28-May-2026", "details": "The Board of Directors of the comoany at the meeting held on Wednesday May 27 2026 recommnded payment of Final Dividend of Rs. 1.00 per Equity Share of the face value of Rs. 10.00 each for the financial year ended March 31 2026 subject to approval of the shareholders at the ensuing Annual General Meeting of the Company.", "source": "BSE" }, { "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication", "datetime": "28-May-2026", "details": "Announcement under Regulation 30 (LODR) - Newspaper Publication for BM held on 27.05.2026", "source": "BSE" }, { "caption": "Compliances - Regulation 32 (1) And (3) - Statament Of Deviation & Variation Report - March 2026", "datetime": "28-May-2026", "details": "Statement of Deviation & Variation Report - March 31 2026", "source": "BSE" } ], "corporate_actions": [ { "img": "board-meeting.svg", "title": "BOARD MEETING", "msg": "<span>No</span> Upcoming Board Meetings", "data": [] }, { "img": "dividend.svg", "title": "DIVIDEND", "msg": "", "data": [ { "txt": "Medicamen Biotech Ltd has declared <strong>10%</strong> dividend, ex-date: 19 Sep 25", "dt": "2025-09-19", "middle_text": "Dividend Alert" } ] }, { "img": "splits.svg", "title": "SPLITS", "msg": "No <strong>Splits</strong> history available", "data": [] }, { "img": "bonus.svg", "title": "BONUS", "msg": "No <strong>Bonus</strong> history available", "data": [] }, { "img": "rights-issues.svg", "title": "RIGHTS", "msg": "No <strong>Rights</strong> history available", "data": [] } ] }

Key Events This Week

25 May: Stock opens at Rs.270.85, rising 1.16% amid positive market sentiment

27 May: Strong Q4 FY26 results announced; valuation shifts to fair

29 May: Stock closes at Rs.270.25, down 4.52% on profit-taking despite quarterly turnaround

Read full news article

Medicamen Biotech Ltd Reports Strong Quarterly Turnaround Amid Long-Term Challenges

2026-05-29 08:00:31

Medicamen Biotech Ltd has demonstrated a notable financial turnaround in the quarter ended March 2026, reversing a negative trend to post its highest quarterly revenue and profit metrics in recent history. Despite ongoing sector headwinds and a challenging broader market environment, the micro-cap pharmaceutical company’s latest results signal a potential inflection point in its operational performance.

Read full news article

Are Medicamen Biotech Ltd latest results good or bad?

2026-05-28 19:23:34

Medicamen Biotech Ltd's latest financial results for Q4 FY26 indicate a significant surge in revenue and net profit, with net sales reaching ₹60.65 crores, reflecting a year-on-year growth of 104.83%. The consolidated net profit also showed a notable increase of 59.50% compared to the same quarter last year, amounting to ₹3.86 crores. This growth trajectory is a marked improvement from the previous year's performance, where the company faced a decline in revenue. However, despite these positive figures, there are underlying concerns regarding the company's operational efficiency. The operating margin, excluding other income, has compressed to 8.97%, down from 9.34% in the previous quarter, continuing a trend of margin compression that has been observed over the past few years. This decline in margins raises questions about the sustainability of the profit growth, particularly as the company has shown a hea...

Read full news article

Medicamen Biotech Ltd is Rated Sell

2026-05-28 10:10:16

Medicamen Biotech Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 05 May 2026. However, the analysis and financial metrics presented here reflect the stock's current position as of 28 May 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and technical outlook.

Read full news article

Medicamen Biotech Q4 FY26: Strong Quarter Masks Deeper Structural Concerns

2026-05-27 22:31:31

Medicamen Biotech Ltd., a research-led pharmaceutical company with presence across 40+ countries, reported consolidated net profit of ₹3.86 crores for Q4 FY26, marking a substantial 76.26% quarter-on-quarter surge and a 59.50% year-on-year increase. However, the micro-cap pharma player, with a market capitalisation of ₹370.00 crores, continues to grapple with structural profitability challenges, elevated valuation multiples, and persistent underperformance against sector benchmarks that have pushed the stock down 33.70% over the past year.

Read full news article

Medicamen Biotech Ltd Valuation Shifts to Fair Amidst Challenging Market Returns

2026-05-27 08:01:06

Medicamen Biotech Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its valuation parameters, moving from an attractive to a fair rating. This change reflects evolving market perceptions amid challenging sector dynamics and a mixed financial performance, prompting investors to reassess the stock’s price attractiveness relative to its historical and peer benchmarks.

Read full news article

When is the next results date for Medicamen Biotech Ltd?

2026-05-21 23:18:14

The next results date for Medicamen Biotech Ltd is scheduled for 27 May 2026....

Read full news article